Stoke Therapeutics

94 articles with Stoke Therapeutics

• Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

  3/15/2023

  Stoke Therapeutics, Inc. today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.

• Stoke Therapeutics to Participate at Upcoming March 2023 Investor Conferences

  2/27/2023

  Stoke Therapeutics, Inc. announced that management will be participating at the following upcoming investor conferences.

• Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

  2/7/2023

  Stoke Therapeutics, Inc. today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET.

• Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

  1/9/2023

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023.

• Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Stoke Therapeutics, Inc. today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT).

• Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

  12/2/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome.

• Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

  11/29/2022

  Seven abstracts related to the Company’s work in Dravet syndrome will be presented, including data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies of STK-001.

• Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - November 14, 2022

  11/14/2022

  Stoke Therapeutics, Inc. today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.

• Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

  11/10/2022

  Stoke Therapeutics, Inc. today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022.

• Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

  8/25/2022

  Stoke Therapeutics today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

• 

  Investors Continue to Fund Data Over Ideas In Current Biotech Downturn

  8/17/2022

  BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.

• Stoke Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

  8/8/2022

  Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the second quarter of 2022 and provided business updates.

• Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

  6/1/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m. ET.

• Stoke Therapeutics Reported First Quarter Financial Results and Provides Business Updates

  5/10/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2022 and provided business updates.

• Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

  5/2/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), today announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002.

• Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

  4/7/2022

  Stoke Therapeutics, Inc. announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado.

• Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Stoke Therapeutics, Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET.

• Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/10/2022

  Stoke Therapeutics, Inc. today reported financial results for the full year ended December 31, 2021 and provided business updates.

• Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

  2/28/2022

  Stoke Therapeutics, Inc. announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

• Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

  1/10/2022

  Acadia Pharmaceuticals and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).